VYNE Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 1, 2024
YARW$15.79+1.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(U.S. dollars in thousands, except per share data)
| Year ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Revenues | ||
| Royalty revenues | $424 | $477 |
| Total Revenues | 424 | 477 |
| Operating Expenses: | ||
| Research and development | 16,307 | 18,385 |
| General and administrative | 13,375 | 16,387 |
| Total Operating Expenses | 29,682 | 34,772 |
| Operating Loss | (29,258) | (34,295) |
| Other income, net | 1,386 | 363 |
| Loss from continuing operations before income taxes | (27,872) | (33,932) |
| Income tax expense | — | 13 |
| Loss from continuing operations | (27,872) | (33,945) |
| (Loss) income from discontinued operations, net of income taxes | (580) | 10,735 |
| Net Loss | $(28,452) | $(23,210) |
| Loss per share from continuing operations, basic and diluted | $(2.72) | $(10.65) |
| (Loss) income per share from discontinued operations, basic and diluted | $(0.06) | $3.37 |
| Loss per share basic and diluted | $(2.78) | $(7.28) |
| Weighted average shares outstanding - basic and diluted | 10,273 | 3,186 |
| Other comprehensive income: | ||
| Unrealized gain on marketable securities, net of tax of $0 | 26 | — |
| Total other comprehensive income | 26 | — |
| Comprehensive loss | $(28,426) | $(23,210) |
F - 3
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.